LPAR1 and metabolic dysfunction-associated steatohepatitis: Furthermore,lysophosphatidic acid receptor 1 (LPAR1) was identified as a therapeutic targeton collagen-producing HSCs, and inhibition of LPAR1 resulted in decreasedcontractility in human HSCs in vitro and reduced liver fibrosisin a choline-deficient high-fat diet rodent model of NASH.45